阳和汤对肾阳虚乳腺癌骨转移患者CXCL12/CXCR4及其下游血管内皮生长因子的影响

Effects of Yanghe Decoction on CXCL12/CXCR4 and VEGF in Patients with Kidney-Yang Deficiency Breast Cancer and Bone Metastasis

目的探究阳和汤对肾阳虚乳腺癌骨转移患者CXCL12/CXCR4及其下游血管内皮生长因子(VEGF)的影响,并观察临床疗效。方法选取2014年1月-2016年12月我院收治的乳腺癌骨转移患者42例,按照随机数表法分为对照组和观察组,各21例。两组患者均接受化疗或内分泌治疗,同时,对照组接受唑来磷酸抗骨转移治疗,观察组在对照组的基础上加服阳和汤。观察两组患者的CXCL12、CXCR4、VEGF表达水平及骨转移灶的治疗效果,记录并比较两组患者的不良反应。结果观察组患者血清CXCL12、CXCR4、VEGF水平均显著低于对照组(P<0.05),骨转移灶治疗效果显著优于对照组(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论阳和汤可改善乳腺癌骨转移患者的治疗效果,可能与其降低CXCL12/CXCR4以及VEGF的表达水平有关。此外,阳和汤并未增加患者的不良反应发生率,安全性较高,值得临床推广使用。

Objective To investigate the ejffects and clinical efficacy of Yanghe decoction on CXCL12/CXCR4 and its downstream vascular endothelial growth factor(VEGF)in breast cancer patients with bone metastases and kidney-Yang deficiency.Methods A total of 42 patients with breast cancer and bone metastases between January 2014 and December 2016 were randomly divided into the control group and the observation group(21 cases in each group).Both groups received conventional chemotherapy measures.The control group were added with zoledronic acid,while the obsenvation group were added with zoledronic acid plus Yanghe decoction.The expressions of CXCL12,CXCR4 and VEGF were detected and the therapeutic effects on bone metastasis were observed.The incidence of adverse reactions in the two groups was recorded and compared.Results The expression levels of serum CXCL12,CXCR4 and VEGF in the observation group were lower than those in the control group(P<0.05).At the same time,the clinical tumor treatment effect of the observation group was better than that of the control group(P<0.05).Finally,the incidence of adverse reactions in the two groups had no statistical difference(P>0.05).Conclusion Yanghe decoction could improve the treatment expectation of breast cancer,possibly due to the reduction of VEGF secretion by CXCL12/CXCR4.In addition,Yanghe decoction did not increase the incidence of adverse reactions.It is worthy of popularization and application.